Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo‐controlled, randomized, phase III clinical trial (ECZTRA 7)*
British Journal of Dermatology2021Vol. 186(3), pp. 440–452
Citations Over TimeTop 1% of 2021 papers
Jan Gutermuth, Andrew Pink, Margitta Worm, Lise Soldbro, Christian Bjerregård Øland, Stephan Weidinger
Abstract
Tralokinumab 300 mg plus TCS as needed was effective and well tolerated in patients with severe AD whose disease was not adequately controlled with CSA or who had contraindications to oral CSA.
Related Papers
- → Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials(2019)58 cited
- → Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic Dermatitis(2022)9 cited
- → Assessment of Patient-Reported Outcomes at 48 Months of Treatment with Dupilumab for Severe Atopic Dermatitis: A Single-Center Real-Life Experience with 126 Patients(2024)8 cited
- → 26691 Rapid and concurrent improvements in the signs and symptoms of atopic dermatitis with baricitinib in the phase 3 study, BREEZE-AD5(2021)1 cited
- → 26670 The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in a baricitinib phase 3 study, BREEZE-AD5(2021)